Pfizer study shows COVID-19 booster can be co-administered with pneumonia shot

[January 12, 2022]  (Reuters) - Pfizer Inc said on Wednesday booster doses of its COVID-19 vaccine produced strong safety and immune responses when co-administered with its pneumonia vaccine in people aged 65 and above in a late-stage study.

The data provides evidence supporting the potential to administer pneumonia shot, PREVNAR 20, and the company's COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunization, Pfizer said.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.